(Q46604917)

23 December 2017

title

Polymerase domain B mutation is associated with hepatitis relapse during long-term lamivudine therapy for chronic hepatitis B. (English)

1 reference

23 December 2017

1 reference

12

Namiki Izumi

1 reference

23 December 2017

author name string

Hiroyuki Nakanishi

1

1 reference

23 December 2017

Masayuki Kurosaki

2

1 reference

23 December 2017

Yasuhiro Asahina

3

1 reference

23 December 2017

Yuko Onuki

4

1 reference

23 December 2017

Ken Ueda

5

1 reference

23 December 2017

Yuki Nishimura

6

1 reference

23 December 2017

Kaoru Tsuchiya

7

1 reference

23 December 2017

Takatoshi Kitamura

8

1 reference

23 December 2017

Masakatsu Uchihara

9

1 reference

23 December 2017

Shozo Miyake

10

1 reference

23 December 2017

Nobuyuki Enomoto

11

1 reference

23 December 2017

language of work or name

1 reference

1 November 2005

1 reference

23 December 2017

published in

Intervirology

1 reference

23 December 2017

volume

48

1 reference

23 December 2017

issue

6

1 reference

23 December 2017

page(s)

381-388

1 reference

23 December 2017

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

cites work

1 reference

Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection

21 January 2018

1 reference

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

Histological improvements after a three-year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did not or did develop

21 January 2018

1 reference

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy

21 January 2018

1 reference

Short-term lamivudine for the treatment of chronic hepatitis B.

21 January 2018

1 reference

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

21 January 2018

1 reference

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

Long-term therapy of chronic hepatitis B with lamivudine.

21 January 2018

1 reference

Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences

21 January 2018

1 reference

Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy

21 January 2018

1 reference

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

Clinical impact of lamivudine resistance in chronic hepatitis B.

21 January 2018

1 reference

Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy

21 January 2018

1 reference

Viral features of lamivudine resistant hepatitis B genotypes A and D.

21 January 2018

1 reference

Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan

21 January 2018

1 reference

Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease

21 January 2018

1 reference

Monitoring low level hepatitis B virus by a newly developed sensitive test

21 January 2018

1 reference

Core promoter/pre-core mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype C.

21 January 2018

1 reference

Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay

21 January 2018

1 reference

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

21 January 2018

1 reference

Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.

21 January 2018

1 reference

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

21 January 2018

1 reference

Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation

21 January 2018

1 reference

Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan.

21 January 2018

1 reference

Identification of HBV DNA sequences that are predictive of response to lamivudine therapy

21 January 2018

1 reference

Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy

21 January 2018

1 reference

The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment.

21 January 2018

1 reference

Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000086065

1 reference

23 December 2017

1 reference

23 December 2017